Migraine drug delay would compound Teva's troubles
TEL AVIV (Reuters) - Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.
from Reuters: Health News https://reut.rs/2FBqIru
http://bit.ly/2zwRqiM